|
|
Article: Gilead's Phase III HBV Data: Viread Stacks Up To Hepsera.
- Article from:
- BIOWORLD Today
- Article date:
- June 8, 2007
- Author:
CopyrightCOPYRIGHT 2007 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Randall Osborne, West Coast Editor
Positive Phase III data with Gilead Sciences Inc.'s Viread for chronic hepatitis B virus didn't surprise Wall Street, and left analysts divided on whether marketing the compound - already prescribed off label - could threaten Hepsera further, the firm's already-cleared therapy, if approved for HBV.
"But if they ultimately get a bigger slice of a growing pie, I don't know if it really matters whether they're selling Viread or Hepsera," noted Sharon Seiler, senior analyst with Punk, Ziegel & Co. in New York, pointing out that the main driver of Gilead's stock remains the HIV franchise.
Hepsera has been ...